국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
FACTOR VIII (ANTIHAEMOPHILIC FACTOR) VON WILLEBRAND FACTOR
CSL Behring GmbH
FACTOR VIII (ANTIHAEMOPHILIC FACTOR) VON WILLEBRAND FACTOR
1000iu via International Unit
Solution for Infusion
Withdrawn
2007-04-18
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Haemate P 1000 IU Powder and solvent for solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Haemate P 1000 is prepared as a powder and solvent for solution for injection. The product reconstituted with 30 ml of water for injection contains approximately 1000 IU human coagulation factor VIII and 2400 IU of vWF:RC of per vial. Each vial contains 1020-1920 mg of dried substance and has a total protein content of 200-440 mg. The potency (IU) for human coagulation factor VIII is determined using the European Pharmacopoeia chromogenic assay against the World Health Organisation (WHO) international standard. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection or infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis and treatment of bleeding in: haemophilia A (congenital factor VIII deficiency). Prophylaxis and treatment of bleeding in von Willebrand's disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia. Haemophilia A The dosage and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on the patient’s clinical condition. The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma). One International Unit (IU) of factor VIII activit 전체 문서 읽기